|
1
|
Hudis CA: Trastuzumab – mechanism of
action and use in clinical practice. N Engl J Med. 357:39–51.
2007.
|
|
2
|
Slamon DJ, Leyland-Jones B, Shak S, et al:
Use of chemotherapy plus a monoclonal antibody against HER2 for
metastatic breast cancer that overexpresses HER2. N Engl J Med.
344:783–792. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Marty M, Cognetti F, Maraninchi D, et al:
Randomized phase II trial of the efficacy and safety of trastuzumab
combined with docetaxel in patients with human epidermal growth
factor receptor 2-positive metastatic breast cancer administered as
first-line treatment: the M77001 study group. J Clin Oncol.
23:4265–4274. 2005. View Article : Google Scholar
|
|
4
|
Buzdar AU, Ibrahim NK, Francis D, et al:
Significantly higher pathologic complete remission rate after
neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin
chemotherapy: results of a randomized trial in human epidermal
growth factor receptor 2-positive operable breast cancer. J Clin
Oncol. 23:3676–3685. 2005. View Article : Google Scholar
|
|
5
|
Gianni L, Eiermann W, Semiglazov V, et al:
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant
trastuzumab versus neoadjuvant chemotherapy alone, in patients with
HER2-positive locally advanced breast cancer (the NOAH trial): a
randomised controlled superiority trial with a parallel
HER2-negative cohort. Lancet. 375:377–384. 2010.
|
|
6
|
Al-Hajj M, Wicha MS, Benito-Hernandez A,
Morrison SJ and Clarke MF: Prospective identification of
tumorigenic breast cancer cells. Proc Natl Acad Sci USA.
100:3983–3988. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liu S, Dontu G and Wicha MS: Mammary stem
cells, self-renewal pathways, and carcinogenesis. Breast Cancer
Res. 7:86–95. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kai K, Nishimura R, Arima N, Miyayama H
and Iwase H: p53 expression status is a significant molecular
marker in predicting the time to endocrine therapy failure in
recurrent breast cancer: a cohort study. Int J Clin Oncol.
11:426–433. 2006. View Article : Google Scholar
|
|
9
|
Therasse P, Arbuck SG, Eisenhauer EA, et
al: New guidelines to evaluate the response to treatment in solid
tumors. European Organization for Research and Treatment of Cancer,
National Cancer Institute of the United States, National Cancer
Institute of Canada. J Natl Cancer Inst. 92:205–216. 2000.
View Article : Google Scholar
|
|
10
|
Kurosumi M, Akashi-Tanaka S, Akiyama F, et
al: Histo-pathological criteria for assessment of therapeutic
response in breast cancer (2007 version). Breast Cancer. 15:5–7.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kuroi K, Toi M, Tsuda H, Kurosumi M and
Akiyama F: Issues in the assessment of the pathologic effect of
primary systemic therapy for breast cancer. Breast Cancer.
13:38–48. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Toi M, Nakamura S, Kuroi K, et al: Phase
II study of preoperative sequential FEC and docetaxel predicts of
pathological response and disease-free survival. Breast Cancer Res
Treat. 110:531–539. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Molina MA, Codony-Servat J, Albanell J,
Rojo F, Arribas J and Baselga J: Trastuzumab (herceptin), a
humanized anti-Her2 receptor monoclonal antibody, inhibits basal
and activated Her2 ectodomain cleavage in breast cancer cells.
Cancer Res. 61:4744–4749. 2001.PubMed/NCBI
|
|
14
|
Gennari R, Menard S, Fagnoni F, et al:
Pilot study of the mechanism of action of preoperative trastuzumab
in patients with primary operable breast tumors overexpressing
HER2. Clin Cancer Res. 10:5650–5655. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nahta R and Esteva FJ: HER2 therapy:
molecular mechanisms of trastuzumab resistance. Breast Cancer Res.
8:2152006. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ginestier C, Hur MH, Charafe-Jauffret E,
et al: ALDH1 is a marker of normal and malignant human mammary stem
cells and a predictor of poor clinical outcome. Cell Stem Cell.
1:555–567. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Morimoto K, Kim SJ, Tanei T, et al: Stem
cell marker aldehyde dehydrogenase 1-positive breast cancers are
characterized by negative estrogen receptor, positive human
epidermal growth factor receptor type 2, and high Ki67 expression.
Cancer Sci. 100:1062–1068. 2009. View Article : Google Scholar
|
|
18
|
Li X, Lewis MT, Huang J, et al: Intrinsic
resistance of tumorigenic breast cancer cells to chemotherapy. J
Natl Cancer Inst. 100:672–679. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Paluch-Shimon S, Wolf I, Goldberg H, et
al: High efficacy of pre-operative trastuzumab combined with
paclitaxel following doxorubicin & cyclophosphamide in operable
breast cancer. Acta Oncol. 47:1564–1569. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chumsri S, Jeter S, Jacobs LK, et al:
Pathologic complete response to preoperative sequential
doxorubicin/cyclophosphamide and single-agent taxane with or
without trastuzumab in stage II/III HER2-positive breast cancer.
Clin Breast Cancer. 10:40–45. 2010. View Article : Google Scholar
|
|
21
|
Chen XS, Wu JY, Huang O, et al: Molecular
subtype can predict the response and outcome of Chinese locally
advanced breast cancer patients treated with preoperative therapy.
Oncol Rep. 23:1213–1220. 2010.PubMed/NCBI
|
